肝脏靶向超顺磁性氧化铁：T2弛豫效应的定量分析

Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects.

作者信息

Pouliquen D, Lucet I, Chouly C, Perdrisot R, Le Jeune J J, Jallet P

机构信息

Laboratoire de Biophysique, Faculte de Medecine, Angers, France.

出版信息

Magn Reson Imaging. 1993;11(2):219-28. doi: 10.1016/0730-725x(93)90026-a.

DOI:10.1016/0730-725x(93)90026-a

PMID:8455432

Abstract

A new liver-directed superparamagnetic iron oxide nanoparticle preparation, MDL, is described. MDL is derived from previously developed MD particles only by modification of the characteristics of the coating:chemical structure and charge. The biodistribution, pharmacokinetics, and intratissular localization of both 59Fe-labeled MD and MDL particles were analyzed. R2 relaxivities determined in aqueous solution are compared to measurements in liver tissue and to R2 of nanoparticles incorporated into synthetic microcapsules, which represent a simplified cell pattern. T2 relaxation effects of both preparations in liver tissue are discussed relative to physical parameters such as iron oxide core dimension, total particle size, and charge, and pharmacological properties such as biodistribution, pharmacokinetics, and extra/intracellular localization.

摘要

本文描述了一种新型的肝脏靶向超顺磁性氧化铁纳米颗粒制剂MDL。MDL仅通过改变包衣的特性（化学结构和电荷）从先前开发的MD颗粒衍生而来。分析了59Fe标记的MD和MDL颗粒的生物分布、药代动力学和组织内定位。将在水溶液中测定的R2弛豫率与肝脏组织中的测量值以及掺入合成微胶囊中的纳米颗粒的R2进行比较，合成微胶囊代表了一种简化的细胞模式。相对于物理参数（如氧化铁核尺寸、总粒径和电荷）以及药理特性（如生物分布、药代动力学和细胞外/细胞内定位），讨论了两种制剂在肝脏组织中的T2弛豫效应。